Speaker: Michael Hocquemiller

0:02:38

LYS-SAF302 AAV gene therapy for MPS IIIA

0:06:19

LYS-GM101 AAV gene therapy for GM1 gangliosidosis

0:01:48

ESGCT 2021 highlights: AAV vector capsid modification for CNS disorders